ArticleMini reviews in medicinal chemistry2026
Mycoproteins and Beyond: Biotechnological Advances in Filamentous Fungal Biomass.
Article in Mini reviews in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid growth of the global population has increased the demand for animal-based proteins, placing considerable pressure on land, feed resources, and space, ultimately making their production costly and environmentally taxing. Filamentous fungi present a promising alternative, serving as a source of mycoprotein and pharmaceutical products. They are rich in high-quality proteins with favorable amino acid profiles, positioning them as an eco-friendly replacement for conventional animal- and plant-derived proteins. In addition, these fungi produce a wide array of secondary metabolites with antibacterial, anticancer, and immunomodulatory properties, highlighting their value in drug discovery. This review discusses recent progress in fungal biomass production through solid-state and submerged fermentation, along with their nutritional relevance and applications in food technology. Importantly, filamentous fungi can grow on inexpensive agricultural byproducts, improving both economic feasibility and environmental sustainability. Their bioactive metabolites also hold strong potential for tackling pressing health issues, establishing filamentous fungi as a versatile biotechnological tool for advancing sustainable food systems and pharmaceutical innovation. The present study contributes to multiple UN Sustainable Development Goals by promoting SDG 2 (zero hunger) through sustainable fungal proteins that enhance food security and nutrition, and SDG 3 (good health and well-being) via bioactive metabolites with therapeutic potential. It advances SDG 9 (Industry, Innovation, and Infrastructure) through innovations in fermentation, genetic engineering, and bioprocessing, while supporting SDG 12 (responsible consumption and production) by utilizing agro-industrial waste within a circular bioeconomy. Moreover, SDG 13 (climate action) is addressed, as mycoprotein production significantly reduces greenhouse gas emissions compared to livestock.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.